Clinical Trial Update: Two-Part Study to Evaluate the Dose Response of SCH 527123 on Sputum Neutrophilia Following Ozone Challenge in Healthy Subjects and Chronic Obstructive Pulmonary Disease (COPD) Patients (P05567 AM7) [Phase 1]

View source ↗

Summary

A Phase 1 two-part dose‑response study evaluated SCH 527123 on sputum neutrophilia after ozone challenge in healthy subjects and COPD patients. The trial, spons…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• SCH 527123

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Chronic Obstructive Pulmonary Disease | Phase 1 | Status: TERMINATED